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T cell non-Hodgkin lymphomas (T-NHLs) represent a heterogeneous group of highly 17 
aggressive malignancies with poor clinical outcomes1. T-NHLs originate from peripheral 18 
T lymphocytes and are frequently characterized by genetic gain-of-function variants in 19 
T cell antigen receptor (TCR) signalling molecules1-4. Although these oncogenic 20 
alterations are thought to drive TCR pathways to induce chronic proliferation and 21 
survival programmes, it remains unclear whether T cells harbour tumour suppressors 22 
that can counteract these events. Using a murine model of human T cell lymphoma, we 23 
demonstrate that the acute enforcement of oncogenic TCR signalling in lymphocytes 24 
drives the strong expansion of these cells in vivo. However, this response is short-lived 25 
and robustly counteracted by cell-intrinsic mechanisms. A subsequent genome-wide in 26 
vivo screen using T cell-specific transposon mutagenesis identified PDCD1, which 27 
encodes the inhibitory receptor Programmed Death-1 (PD-1), as a master gene 28 
suppressing oncogenic T cell signalling. Mono- and bi-allelic PDCD1 deletions are also 29 
recurrently observed in human T cell lymphomas with frequencies that can exceed 30%, 30 
indicating high clinical relevance. Mechanistically, PD-1 activity enhances PTEN levels 31 
and attenuates AKT and PKC signalling in pre-malignant cells. In contrast, a homo- or 32 
heterozygous deletion of PD-1 allows unrestricted T cell growth after an oncogenic insult 33 
and leads to the rapid development of highly aggressive lymphomas in vivo that are 34 
readily transplantable to recipients. Altogether, these results indicate that the inhibitory 35 
PD-1 receptor is a potent haploinsufficient tumour suppressor in T-NHLs that is 36 
frequently altered in human disease. These findings extend the known physiological 37 
functions of PD-1 beyond the prevention of immunopathology after antigen-induced T 38 
cell activation and have implications for T cell lymphoma therapies and for current 39 
strategies that target PD-1 in the broader context of immuno-oncology. 40 
41 
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Recent integrated molecular studies of human T cell lymphomas have identified activating 42 
mutations in signalling molecules that regulate T cell antigen receptor (TCR) pathways as a 43 
hallmark of most T cell non-Hodgkin lymphoma (T-NHL) subtypes1-6. These alterations 44 
affect antigen receptor proximal regulators, PI3K elements that engage the AKT pathway, 45 
mediators of antigen-induced NF-κB activation, such as PKCs and CARD11, and various 46 
other factors1-6. A specific chromosomal translocation that is recurrently detected in human 47 
peripheral T cell lymphoma cases is t(5;9)(q33;q22)7,8, which fuses the antigen receptor 48 
kinase genes ITK and SYK. The chimeric ITK-SYK protein exhibits constitutive tyrosine 49 
kinase activity and enforces the oncogenic activations of TCR pathways via the activation of 50 
PLCγ, PI3K/AKT signalling and PKC/NF-κB8. We used this fusion protein to experimentally 51 
explore the pathomechanisms of T cell lymphomagenesis, a paradigm that has been 52 
successfully exploited in several other haematopoietic malignancies with recurrent 53 
chromosomal translocations9. To generate a genetically tractable model of human T-NHL, we 54 
had introduced a patient-derived ITK-SYK together with a eGFP cDNA into the murine 55 
Rosa26 locus preceded by a loxP-flanked STOP cassette (LSL; Rosa26LSL-ITK-SYK mice)8. 56 
Crossing Rosa26LSL-ITK-SYK mice to CD4-Cre transgenic mice for the T cell-specific ITK-57 
SYK/eGFP expression induced fully penetrant aggressive T cell lymphomas in the offspring 58 
(ITK-SYKCD4-Cre mice) that exhibited molecular, clinical and pathological features of the 59 
human disease8 (Extended Data Fig. 1a, b, c). Although the constitutively active CD4-Cre 60 
transgene drives continuous ITK-SYK expression in millions of polyclonal T cells, the final 61 
lymphomas are typically clonal (Extended Data Fig. 1d)8. In contrast to polyclonal T cells 62 
from young ITK-SYKCD4-Cre mice these clonal lymphoma cells transmit the disease to 63 
recipient mice (Extended Data Fig. 1e) indicating that they possess genetic alterations in 64 
addition to ITK-SYK expression, which promote malignancy. 65 
To assess the evolution of these cancers in a controlled manner, we crossed Rosa26LSL-ITK-SYK 66 
mice with animals that allow tamoxifen-inducible Cre activation in CD4+ T cells (CD4-67 
CreERT2 mice)10. We triggered single pulses of Cre activity in subsets of lymphocytes in the 68 
progeny (ITK-SYKCD4-CreERT2 mice) (Fig. 1a, b, c). ITK-SYK and eGFP expression in 69 
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individual lymphocytes led to a rapid expansion of these cells in vivo (Fig. 1a). The maximal 70 
frequencies of ITK-SYK+CD4+ T cells increased with increasing doses of tamoxifen (r=0.99). 71 
However, after this expansion phase, the ITK-SYK+ compartments again contracted (Fig. 1a). 72 
To characterize these two phases, we again induced ITK-SYK/eGFP expression in T cells in 73 
vivo and then FACS-sorted recombined CD4+ T cells for an in vitro RNAseq analysis (Fig. 74 
1b). Gene set enrichment analysis (GSEA) revealed enrichment in the signatures 75 
Ishida_E2F_targets11, Hallmark_G2M_checkpoint12 and Whitfield_cell_cycle_literature13 in 76 
the ITK-SYK-expressing cells at day 4 compared with that of naïve CD4+ T cells 77 
demonstrating a highly proliferative phenotype. However, at day 7, the proliferative 78 
signatures were significantly downregulated (p<0.01) along with the declining ITK-SYK+ T 79 
cell numbers in vivo, indicating that T cells possess tumour-suppressive mechanisms that can 80 
counteract oncogenic T cell signalling within days. Nevertheless, within one year, two of 81 
three mice that received the highest dose of tamoxifen (1 mg) developed ITK-SYK/eGFP-82 
expressing CD4+ T cell lymphomas (Fig. 1c), with organ infiltration by malignant 83 
lymphoblasts (Extended Data Fig. 1f, g), which demonstrated that the tumour-suppressive 84 
pathways can be disrupted. Because the onset of these lymphomas was correlated with the 85 
initial frequency of the ITK-SYK-expressing T cells (Fig. 1c; p=0.005), these tumour-86 
enabling secondary events are presumably stochastic in nature. 87 
To reveal the mechanisms that enable full T cell transformation after oncogenically 88 
enforced TCR signalling we designed a genome-wide forward genetic screen (Fig. 2a) using 89 
the piggyBac (PB) transposition system for in vivo mutagenesis14,15. To achieve spatially 90 
restricted transposition in only the ITK-SYK-sensitized T cells, we crossed Rosa26LSL-ITK-SYK 91 
to CD4-Cre mice and animals conditionally expressing the PB transposase from the Rosa26 92 
locus (Rosa26LSL-PB) and to ATP2-H32 transgenic mice harbouring mutagenic ATP 93 
transposon cassettes that could be mobilized by PB15,16. The quadruple-transgenic progeny 94 
developed accelerated T cell lymphomas after transposon mobilization (Extended Data Fig. 95 
2a, b, c). The integration sites were recovered from FACS-sorted eGFP+ cancer cells by 96 
multiplexed insertion site sequencing (QISeq)15 followed by statistical analyses17 to identify 97 
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the genomic regions that were more frequently hit by transposons than expected by chance 98 
(Fig. 2a). Remarkably, the top ranking common insertion site (CIS) (genomic region with the 99 
highest transposon insertion density) with the highest significance (p=0.87x10-31) across the 100 
genome was located at the Pdcd1 locus that encodes the inhibitory receptor Programmed 101 
Death-1 (PD-1)18 (Fig. 2b and Extended Data Fig. 2e). These insertions did not co-exist with 102 
common insertions in other loci and resulted in Pdcd1-transposon fusion transcripts 103 
(Extended Data Fig. 2f). Some cancers had multiple Pdcd1 insertions that most likely 104 
reflected bi-allelic inactivation and/or local transposon hopping with gene trapping in 105 
subclones. Lymphomas with Pdcd1 transposon insertions exhibited reduction in or lack of 106 
PD-1 protein and Pdcd1 mRNA expression (Fig. 2c and Extended Data Fig. 2d). 107 
PD-1 functions to restrict antigen-induced TCR responses at tolerance checkpoints with 108 
persistent antigenic stimulation for the prevention of autoimmunity18 and has received 109 
considerable attention because it limits antigen-driven T cell proliferation and survival in 110 
suppressive microenvironments in cancer and chronic infection19. Our genetic screen 111 
indicated that PD-1 might also possess unrecognized functions as a tumour suppressor in T 112 
cell lymphoma. To study potential PDCD1 alterations in human T cell lymphoma, we 113 
performed a meta-analysis of five published studies2-6. Strikingly, we found genomic PDCD1 114 
alterations in 36 of 158 cases (23%) (Extended Data Table 1). The predominant mutation type 115 
was copy number aberration (33 cases). Among these, focal deletions with mono- or bi-allelic 116 
PDCD1 loss were prominent (Fig. 2d, Extended Data Table 1 and Extended Data Fig. 3a, b). 117 
The highest proportion of homo- or heterozygous PDCD1-deleted cases (36%, 13 out of 36) 118 
was found in a group of patients with advanced stage IV cutaneous T cell lymphoma3 119 
(Extended Data Table 1). A single case with PDCD1 genomic gain exhibited defective 120 
PDCD1 mRNA expression (Extended Data Fig. 3a). In light of our genetic screen, these 121 
frequent homo- or heterozygous PDCD1 deletions in human T-NHL strongly suggest that 122 
PD-1 is functionally relevant in lymphoma pathogenesis.  123 
In normal T cells, the PD-1 expression is upregulated upon TCR ligation19 and PD-1 124 
subsequently provides feedback for the prevention of autoimmunity. To investigate whether 125 
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oncogenic T cell signals can also induce PD-1 expression, we introduced ITK-SYK variants 126 
into Jurkat T cells8. ITK-SYK signalling drives PD-1 expression in a kinase-dependent 127 
manner (Extended Data Fig. 4a). In transduced primary human CD4+ T cells, we also detected 128 
the ITK-SYK kinase-mediated upregulation of PD-1 expression (Extended Data Fig. 4b). 129 
Likewise, acute ITK-SYK expression in primary CD4+ T cells from tamoxifen-treated ITK-130 
SYKCD4-CreERT2 mice drives also robust PD-1 protein and mRNA expression (Fig. 3a, b and 131 
Extended Data Fig. 4c). Moreover, the analysis of human T-NHL samples (n=50)2,6, which 132 
did or did not exhibit the activation of the gene signature 133 
GO_antigen_receptor_mediated_signaling_pathway (195 genes) demonstrated that the 134 
aberrant activation of TCR signalling pathways was correlated with significantly upregulated 135 
PDCD1 mRNA expression (Fig. 3c, d) in these tumours. In addition, within this patient 136 
group, loss of one or two PDCD1 alleles led to a significantly reduced or completely absent 137 
PDCD1 mRNA expression (Fig. 3e). Thus, PDCD1 expression is upregulated after oncogenic 138 
T cell signalling in murine and human cells, and the loss of the PDCD1 locus in human T-139 
NHL impairs PDCD1 mRNA expression. 140 
PD-1 ligation dampens physiological antigen-mediated T cell activation by enhancing 141 
the tumour suppressor phosphatase PTEN20 and attenuating the PI3K/AKT21 and PKCθ/NF-142 
κB pathways22. Because these two cascades are critical for lymphomagenesis, we tested 143 
whether they were sensitive to PD-1 ligation after oncogene induction. We activated ITK-144 
SYK in vivo by injecting tamoxifen into ITK-SYKCD4-CreERT2 mice, isolated CD4+ cells, 145 
stimulated them with PD-L1 and subsequently performed an intracellular Phosflow analysis. 146 
The engagement of PD-1 increased PTEN protein levels and attenuated the AKT and PKCθ 147 
activities in pre-malignant ITK-SYK expressing cells (Fig. 3f). Thus, oncogenic T cell 148 
signalling upregulates PD-1 expression and PD-1 functions to suppress oncogenic effector 149 
pathways. 150 
To study the oncogene-PD-1 loop in tumour suppression in vivo, we crossed the 151 
Rosa26LSL-ITK-SYK and CD4-CreERT2 alleles on a PD-1-deficient background23 and triggered 152 
ITK-SYK expression via tamoxifen in the offspring. As previously observed, the marked 153 
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expansion of ITK-SYK+/eGFP+ T cells was robustly counter-regulated in the presence of PD-154 
1 (Fig. 4a). In sharp contrast, without PD-1, the ITK-SYK+ T cells expanded without 155 
restriction, and all tamoxifen-treated ITK-SYKCD4-CreERT2;PD-1-/- animals had to be euthanized 156 
after only one week because of a strong accumulation of lymphoblastoid ITK-SYK+PD-1-/- 157 
CD4+ T cells in the lymphoid tissues and invasive growth with a noncohesive pattern into the 158 
solid organs (Fig. 4a and Extended Data Fig. 5a, b, c). Upon transplantation these ITK-159 
SYK+/eGFP+PD-1-/- CD4+ T cells continued to expand invasively and transmitted the lethal 160 
disease to recipients demonstrating that these cells were fully transformed malignant 161 
lymphocytes (Fig. 4b and Extended Data Fig. 5d, e, f, g). In parallel, we incubated CD4+ T 162 
cells from Rosa26LSL-ITK-SYK and Rosa26LSL-ITK-SYK;PD-1-/- mice without Cre transgenes with 163 
the recombinant TAT-CRE fusion recombinase24 in vitro and injected 5x105 treated cells into 164 
syngeneic C57BL/6 wild-type mice, which had not received any pre-conditioning treatment 165 
(Extended Fig. 6a, b, c, d, e, f). The TAT-CRE-treated ITK-SYK-expressing CD4+ T cells 166 
from PD-1-competent donors (Rosa26LSL-ITK-SYK) disappeared over time (Extended Data Fig. 167 
6c). In contrast, those from PD-1-deficient donors (Rosa26LSL-ITK-SYK;PD-1-/-) robustly 168 
expanded and induced lethal infiltrative lymphomas that could be serially transplanted into 169 
syngeneic animals  (Extended Data Fig. 6g, h, i, j). Thus, the absence of PD-1 in peripheral T 170 
cells enables an appropriate oncogenic signal to directly create an aggressive cancer. 171 
Because mono-allelic deletions are the most common type of PDCD1 alteration in 172 
human T-NHL (see Fig. 2d, Extended Data Table 1 and Extended Data Fig. 3b), we also 173 
treated heterozygous ITK-SYKCD4-CreERT2;PD-1+/- mice with tamoxifen. Intriguingly, all 174 
heterozygous ITK-SYKCD4-CreERT2;PD-1+/- mice succumbed to invasive transplantable 175 
lymphomas after tamoxifen injection (Fig. 4c and Extended Data Fig. 7a, b, c, d, e, f, g, h, i, 176 
j), establishing PD-1 as a haploinsufficient tumour suppressor.  177 
The inhibition of the PD-1/PD-L1 interaction with antibodies against PD-1 or PD-L1 is 178 
heavily exploited in the clinic to activate T cell immunity against multiple cancer cell types25. 179 
Therefore, we next treated ITK-SYKCD4-CreERT2 mice with checkpoint inhibitors (anti-PD-L1 180 
or anti-PD-1) after tamoxifen induction (Fig. 4d, e, f and Extended Data Fig. 8a, b, c, e). 181 
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Strikingly, similar to a genetic PD-1 deletion, anti-PD-L1 treatment beginning one day after 182 
tamoxifen induction lead to an immediate invasive ITK-SYK+ T cell proliferation (Fig. 4d, e 183 
and Extended Data Fig. 8a, b, c). Likewise, treatment of ITK-SYKCD4-CreERT2 mice with anti-184 
PD-L1 or anti-PD-1 antibodies during the contraction phase of the ITK-SYK+ cell 185 
compartment (ten days after tamoxifen treatment) also induced lethal lymphoproliferation 186 
(Fig. 4f and Extended Data Fig. 8e). However, these cells were unable to transmit the disease 187 
when transplanted into non-antibody-treated recipients (Extended Data Fig. 8d). Thus, 188 
although these checkpoint inhibitors accelerate the growth of T cells with oncogenically 189 
sensitized TCR pathways, their pharmacological effects are only transient in contrast to the 190 
effect of T cell intrinsic Pdcd1 gene deletion. 191 
We demonstrated above that the ligation of PD-1 enhances PTEN levels and attenuates 192 
PI3K/AKT and PKCθ function after ITK-SYK signalling (see Fig. 3f). PD-1 signalling in a 193 
PD-1-transduced human lymphoma cell line also enhances PTEN and attenuates PI3K/AKT 194 
and PKCθ (Extended Fig. 9a, b, c). Consistently, in murine PD-1-deficient ITK-SYK+ 195 
lymphomas, PTEN levels are reduced and AKT and PKCθ activity is enhanced (Fig. 4g), 196 
suggesting that PDCD1 deletions promote tumourigenesis, at least in part, via these 197 
mechanisms. To study the functional relevance of PI3K/AKT enforcement, we incubated PD-198 
1-deficient lymphoma cells in vitro with the PI3K inhibitor idelalisib, which is currently 199 
undergoing clinical development for selected B cell malignancies26. PI3K inhibition 200 
downregulated AKT activity and induced death of ITK-SYK+PD-1-/- lymphoma cells 201 
(Extended Data Fig. 9d). Finally, we treated mice that harbour ITK-SYK+PD-1-/- lymphomas 202 
with idelalisib in vivo. PI3K inhibition significantly extended the lifespan of these mice, 203 
demonstrating that the activity of PI3K/AKT signalling is critical for lymphomas with Pdcd1 204 
deletion (Fig. 4h and Extended Data Fig. 9e). 205 
In conclusion, our studies establish PD-1 as a powerful haploinsufficient tumour 206 
suppressor in T cell lymphoma. Thus, PD-1 not only functions to prevent autoimmunity after 207 
chronic antigen exposure and physiological TCR ligation but also unexpectedly counteracts 208 
oncogenic T cell signalling pathways within precancerous cells. The deficiency in PD-1 in T 209 
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cell lymphoma promotes PI3K/AKT activity, and our preclinical data suggest PI3K inhibitors 210 
as candidate drugs for the treatment of these tumours. Checkpoint blockade with anti-PD-1 or 211 
anti-PD-L1 to relieve T cell inhibition in tumour microenvironment27 is a revolutionary 212 
treatment of multiple malignancies25 and is currently being explored in T-NHL. Our findings 213 
that these checkpoint inhibitors can accelerate and/or reactivate T cell clones with 214 
oncogenically activated TCR pathways indicate the need for special consideration when using 215 
these in T-NHL patients. In addition, new clinical trials using CRISPR/Cas9-mediated gene 216 
editing to bi-allelically disrupt the PDCD1 locus in peripheral T cells of cancer patients are 217 
being initiated with the goal of enhancing anti-tumour immune responses28. Reports have 218 
suggested that these treatments could trigger autoimmune reactions28. Our data demonstrating 219 
that a suitable oncogenic hit on PD-1-deficient T cells is sufficient for their direct malignant 220 
transformation puts additional caution on these gene editing approaches. 221 
222 
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Methods 223 
Mice. Mice of both sexes aged 6-12 weeks were used for all experiments. Littermate controls 224 
were used whenever possible. Randomization and blinding were not performed. Rosa26LSL-225 
ITK-SYK mice8 were backcrossed for more than 12 generations on a C57BL/6 genetic 226 
background. CD4Cre-ERT2 10 mice were crossed to the Rosa26LSL-ITK-SYK strain to generate 227 
the ITK-SYKCD4Cre-ERT2 mice. Rosa26LSL-PB mice16 were crossed to Rosa26LSL-ITK-SYK mice to 228 
generate the Rosa26LSL-ITK-SYK;Rosa26LSL-PB strain, and ATP2-H3214 mice were crossed to 229 
CD4-Cre mice to generate the ATP2;CD4-Cre transgenic animals. Both resulting lines were 230 
crossed again to generate the quadruple-transgenic Rosa26LSL-ITK-SYK;Rosa26LSL-231 
PB;ATP2;CD4-Cre mice and control cohorts. C57BL/6, NOD/SCID Il2rg−/− (NSG, 005557), 232 
CD4-Cre (02207129) and PD-1-/- (02827623) mice were purchased from the Jackson 233 
Laboratory, Bar Harbor, Maine, USA. CD4-Cre and PD-1-/- mice were backcrossed on a 234 
C57BL/6 genetic background. All animal experiments were performed according to local 235 
guidelines (Regierung von Oberbayern, Munich, Germany). Mice were euthanized if they 236 
exhibited signs of lymphoma (lymph node enlargement, palpable tumour, laboured breathing, 237 
ascites) or if they lost 20% or more of their body weight. None of the approved thresholds 238 
were exceeded at any time. 239 
 240 
Flow cytometry. Flow cytometric analyses were performed using standard protocols. Primary 241 
cell suspensions from the spleen, lymph nodes, or peripheral blood were directly labelled. 242 
Single-cell suspensions from the liver, kidney, or lung were first purified by Percoll 243 
(17089101, GE Healthcare, Chicago, Illinois, USA) gradient centrifugation. Fluorescently 244 
labelled antibodies against the following surface proteins were used for staining mouse cells: 245 
TCRβ (APC/Cy7-labeled anti-mouse TCR β chain antibody, 10922), CD4 (Pacific blue-246 
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labelled anti-mouse CD4 antibody, 100428), CD44 (PE-labelled anti-mouse/human CD44 247 
antibody, 103008), and PD-1 (APC-labelled anti-mouse CD279 (PD-1) antibody, 135210). 248 
For the human cells, the following antibodies were used: PD-1 (APC-labelled anti-human 249 
CD279 (PD-1) antibody, 329908), CD3 (PE/Cy7-labelled anti-human CD3 antibody, 300420) 250 
and PD-L1 (PE-labelled anti-human CD274 (B7-H1, PD-L1) antibody, 329706). Fc receptor 251 
blocking was performed with anti-CD16/32 antibodies (101320 or 422302). All antibodies 252 
were purchased from BioLegend, San Diego, California, USA. The data were acquired using 253 
a FACSCanto II flow cytometer (Becton, Dickinson and Company, Franklin Lakes, New 254 
Jersey, USA). FlowJo software (FlowJo LLC, Ashland, Oregon, USA) was used for data 255 
analyses. 256 
 257 
GeneScan analysis of TCR gene rearrangements. Genomic DNA was extracted (DNeasy, 258 
Qiagen, Venlo, The Netherlands) from magnetically purified (130104454, Miltenyi Biotec, 259 
Bergisch Gladbach, Germany) CD4+ T cells from C57BL/6 mice (Control), young ITK-260 
SYKCD4-Cre mice and lymphoma-bearing ITK-SYKCD4-Cre mice. GeneScan analysis to detect 261 
TCR gene rearrangements was performed as previously described8. In summary, VDJ 262 
rearrangements of the TCRβ and TCRγ loci were amplified via five PCR reactions with 26 263 
primers in total, with three primers labelled with 5’-FAM fluorochromes. Fluorochrome-264 
labelled PCR products were then size-separated and scanned via capillary electrophoresis. 265 
 266 
Induction of spontaneous ITK-SYK expression in peripheral T cells. Tamoxifen (T5648, 267 
Sigma-Aldrich, St. Louis, Missouri, USA) was dissolved in pure ethanol (with heating) and 268 
subsequently diluted in migliol (3274, Caesar & Loretz, Hilden, Germany) to a final 269 
concentration of 10 mg/ml. To induce the expression of ITK-SYK in a small fraction of 270 
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peripheral CD4+ T cells, ITK-SYKCD4-CreERT2, ITK-SYKCD4-CreERT2;PD-1+/- or ITK-SYKCD4-271 
CreERT2;PD-1-/- mice were given tamoxifen at the indicated doses via intraperitoneal (i.p.) 272 
injection. 273 
 274 
RNA. For the RNAseq experiments, ITK-SYKCD4-CreERT2 mice were given single i.p. 275 
injections of 1 mg tamoxifen per mouse (T5648, Sigma-Aldrich). Forty-eight hours after 276 
injection, the spleens were harvested; the single-cell suspensions were subjected to CD4+ T 277 
cell purification by magnetic depletion (130104454, Miltenyi Biotec), and the cells were then 278 
cultured in vitro. At the indicated time points, the T cells were FACS-sorted (FACSAria, 279 
Becton, Dickinson and Company) again for viability and eGFP expression. Total RNA was 280 
extracted from approximately 100,000 cells using spin columns (RNeasy Micro Plus Kit, 281 
Qiagen). Library preparation was performed from 1 ng total RNA with the SMART-Seq v2 282 
Ultra Low Input RNA Kit (Takara Bio Inc., Kusatsu, Shiga, Japan), and SE-50 bp sequencing 283 
was performed on Illumina HiSeq2000 machines (Illumina, San Diego, California, USA). 284 
Read alignment to the mm10 genome and transcriptome assembly were performed using 285 
HISAT230 and StringTie31, respectively. Differential expression was assessed with 286 
Ballgown32. GSEA was performed with BubbleGUM33; to assess proliferation, the following 287 
signatures were selected: Whitfield_cell_cycle_literature13, Ishida_E2F_targets11 and 288 
Hallmark_G2M_checkpoint12. RNAseq data for naïve murine CD4+ T cells were retrieved 289 
from the Gene Expression Omnibus data repository series GSE8331534 (samples 83-85), re-290 
aligned to the mm10 genome using HISAT2 and then processed in a manner similar to that 291 
used for the other samples. 292 
For Pdcd1 mRNA quantification within lymphoma cells from Rosa26LSL-ITK-SYK;Rosa26LSL-293 
PB;ATP2;CD4-Cre mice, total RNA was extracted from eGFP+ FACS-sorted spleen-derived 294 
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lymphocytes using spin-columns and then reverse transcribed (M0368L, NEB, Ipswich, 295 
Massachusetts, USA). The Pdcd1 and eGFP cDNA was simultaneously quantified using 296 
transcript-specific probes (4331182, Mm01285676_m1, FAM-MGB and 4448484, 297 
Mr03989638_mr, VIC-MGB_PL, Thermo Fisher Scientific, Waltham, Massachusetts, USA) 298 
on a droplet digital PCR system (QX200 Droplet Digital PCR System, 1864001, Bio-Rad, 299 
Hercules, California, USA). Subsequently, the amount of eGFP-normalized Pdcd1 cDNA 300 
was categorized based on the presence of transposon cassettes within the Pdcd1 locus. 301 
The primers for the identification of the Pdcd1-transposon mRNA splice junctions are listed 302 
in Supplementary Table 1. 303 
 304 
Quantitative insertion-site sequencing and identification of common integration sites. 305 
Lymphoma cells from Rosa26LSL-ITK-SYK;Rosa26LSL-BP;ATP2;CD4-Cre mice were harvested 306 
by generating single-cell suspensions from the spleens and lymph nodes and then sorting for 307 
5x106 viable eGFP+CD4+ T cells. Genomic DNA was extracted using spin columns. The 308 
transposon insertion-sites were recovered using QiSeq, a splinkerette-PCR-based method for 309 
semi-quantitative insertion-site sequencing36. Bioinformatics data processing, mapping of 310 
sequence reads and statistical analyses to identify CIS using TAPDANCE were performed as 311 
described earlier36. The CISs that were also detected in the data from control animals without 312 
the ITK-SYK transgene were excluded from analysis. 313 
 314 
Genomic PDCD1 alterations in human T cell lymphoma. PubMed and Google Scholar 315 
were searched for published studies on human T cell malignancies that included WGS, WES, 316 
or targeted sequencing data. The supplementary data from the identified studies were 317 
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searched for single nucleotide variants, small indels, and copy number aberrations (CNAs) 318 
that affect the PDCD1 locus. Whole-genome sequencing data (aligned BAM files, 47 tumour-319 
normal pairs)2 were downloaded from the European Genome-phenome Archive with 320 
permission. Whole exome sequencing data (aligned BAM files, 34 tumour-normal pairs)6 321 
were downloaded from the Sequence Read Archive (accession PRJNA285408). The BAM 322 
files were subjected to a copy number analysis using Control-FREEC36. The copy numbers 323 
were calculated for each sample in windows of 3 kb with steps of 1 kb using tumour and 324 
corresponding normal samples as inputs. Breakpoint analysis, segmentation and absolute copy 325 
number calling were performed with Control-FREEC. The resulting segments and copy 326 
number ratios (tumour/normal) were transformed to a log2 scale and plotted for all tumours 327 
along chromosome 2 for visual inspection.  328 
 329 
GSVA and PDCD1 FPKM analyses in human T cell lymphoma. RNAseq data of human 330 
T-NHL patients were downloaded from the Sequence Read Archive (accession 331 
PRJNA285408)6 and the European Genome-phenome Archive2. Reads were extracted in fasta 332 
format from sra or bam files and aligned to the hg19 genome with HISAT230 and processed 333 
with StringTie31 and Ballgown32. All samples with available genomic data (WES or WGS) 334 
were included in the analysis. Using GSVA37 for each sample, an enrichment score was 335 
calculated based on the gene set GO_antigen_receptor_mediated_signaling_pathway (195 336 
genes) from the MSigDB database: Twenty-eight of fifty samples that were identified as 337 
positive for the signature were included in the subsequent analysis. FPKM values for PDCD1 338 
were extracted and statistically compared based on the enrichment score and the PDCD1 copy 339 
number status as indicated in the figure legend. 340 
 341 
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Cloning. To generate the PD-1 vector, first, the 3' LTR of the lentiGuide-Puro Plasmid 342 
(52963, Addgene, Cambridge, Massachusetts, USA) was replaced by an HIV/MSCV hybrid 343 
LTR as described38. The LTR-modified backbone and the central polypurine tract (cPPT) 344 
sequence was then amplified with the BsmBI restriction site-containing oligos BBf, BBr or 345 
CPPTf and CPPTr. Finally, the PDCD1 cDNA was cloned together with an IRES-GFP and a 346 
cPPT sequence into the modified backbone via Golden Gate Assembly using the PDCD1f and 347 
PDCD1r primers for the cDNA and the IRESGFPf and IRESGFPr primers for the IRES-GFP 348 
sequence. The PD-1 YFYF plasmid was subsequently generated using sequential site-directed 349 
mutagenesis with the Y223F and Y248F primer pairs. The oligo sequences are listed in 350 
Supplementary Table 2. 351 
 352 
 353 
Cell culture. T cells were cultured in RPMI-1640 medium containing 20% FCS in the case of 354 
primary cells, 10% FCS in the case of HuT 78 T-NHL cells39 or 5% FCS in the case of Jurkat-355 
Eco T cells. To culture the Phoenix-Eco and Phoenix-Ampho packaging cells, we used 356 
DMEM with 10% FCS. HEK293FT cells were cultured in 5% FCS containing DMEM. The 357 
HuT 78 cell line was authenticated at the DSMZ via STR profiling (Leibniz Institute DSMZ-358 
German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany). 359 
Otherwise, no authentication of the cell lines was performed. All cell lines were routinely 360 
tested for mycoplasma infection.  361 
For the generation of dendritic cells, Ficoll (Ficoll-Paque PLUS, 17144002, GE Healthcare) 362 
gradient-separated PBMCs from healthy donors were magnetically enriched for monocytes 363 
(130050201, Miltenyi Biotec). Next, the cells were cultured for six days in the presence of 364 
recombinant IL-4 (20 ng/ml, 20004, Peprotech, Rocky Hill, New Jersey, USA) and GM-CSF 365 
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(100 ng/ml, 30003, Peprotech). Finally, differentiated dendritic cells were induced to express 366 
PD-L1 with a 24-hours Interferon-γ stimulation (100 ng/ml, 30002, Peprotech).   367 
All human PBMCs were collected from healthy donors with informed consent according to 368 
the protocols approved by the Institutional Review Boards. The study protocol was approved 369 
by the local ethics committee (Ethics Committee of the Medical Faculty, Klinikum rechts der 370 
Isar, Technical University of Munich, Germany). 371 
For the in vitro experiments using idelalisib (CAL-101, GS-1101, PI3Kδ inhibitor; S2226, 372 
Selleckchem, Houston, Texas, USA), the inhibitor was dissolved in DMSO, and the cell 373 
culture medium was supplemented with the indicated concentration of the compound or 374 
DMSO (as a control).  375 
 376 
Retroviral infections. Generation of ecotropic viral particles containing GFP, ITK-SYK or 377 
ITK-SYKKD constructs and infection of Jurkat-Eco cells were performed as previously 378 
described8. To generate amphotropic retrovirus, Phoenix-Ampho cells were grown in 15 cm 379 
dishes and transfected using FuGENE (Promega, Madison, Wisconsin, USA) with 10 μg ITK-380 
SYK or ITK-SYKKD 8. The media was changed 8 hours after transfection. The viral 381 
supernatant was collected 36 hours after transfection, passed through a 0.45 μm filter and 382 
used fresh or snap-frozen for later. Activated primary human CD4 T-cells were spinfected 383 
with RetroNectin-coated (Takara Bio Inc.) 6-well plates (5 mg/ml). For the production of 384 
lentiviral particles, we used HEK293FT cells. FuGENE-based transfection was performed 385 
with 17 μg pCMV delta R8.2, 10 μg pHCMV-10A1 and 10 μg PD-1 or PD-1 YFYF. HH cells 386 
were spinfected with the lentivirus on RetroNectin-coated 6-well plates (5 mg/ml). 387 
 388 
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Primary human T-cell isolation. Human PBMCs were isolated by Ficoll gradient 389 
centrifugation of fresh blood obtained from healthy donors. CD4 T-cells were enriched by 390 
magnetic depletion (130096533, Miltenyi Biotec) and stimulated with immobilized anti-CD3 391 
antibody (10 μg/ml, purified anti-human CD3 antibody, 300332, BioLegend), soluble anti-392 
CD28 antibodies (2 μg/ml, purified anti-human CD28 antibody, 302934, BioLegend) and 10 393 
ng/ml IL-2 (20002, Peprotech). After 48 hours, the cells were infected with retroviruses. Five 394 
days later, the T-cells were stimulated again with 2 μg/ml soluble anti-CD28 (302934, 395 
BioLegend) antibodies and analysed for PD-1 expression by flow cytometry. 396 
 397 
Transplantation experiments. For ITK-SYKCD4-Cre transplantation experiments, splenocytes 398 
from donor mice were harvested and single-cell suspensions were FACS-sorted for eGFP 399 
expression. Subsequently, 3x106 sorted cells were intravenously injected into C57BL/6 400 
recipient mice. 401 
For transplantation experiments into NSG mice, splenocytes from donor mice were harvested 402 
on day 5 or 7 after tamoxifen induction, subjected to CD8 T cell depletion (11447D, Thermo 403 
Fisher Scientific) and then i.v.-injected into NSG mice.  404 
For transplantation experiments without Cre transgenes, splenocytes from Rosa26LSL-ITK-SYK 405 
and Rosa26LSL-ITK-SYK;PD-1-/- mice were harvested, and the CD4+ T cells were purified and 406 
subsequently incubated for one hour in serum-free media (31985062, Thermo Fisher 407 
Scientific) supplemented with 1 μM recombinant TAT-CRE protein (EG1001, Excellgen Inc., 408 
Rockville, Maryland, USA). After extensive washing, the cells were intravenously injected 409 
into C57BL/6 recipients. For transplantation into secondary C57BL/6 recipient mice, the 410 
spleens from diseased primary recipients were harvested, FACS-sorted for eGFP expression, 411 
washed and intravenously injected (1x105 cells/recipient) into wild-type C57BL/6 mice. 412 
 413 
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In vivo PI3K inhibitor treatment. For PI3K inhibitor treatment, recipient NSG mice were 414 
injected with 5x104 eGFP+ T-cells together with CD8-depleted (11447D, Thermo Fisher 415 
Scientific) splenocytes from ITK-SYKCD4-CreERRT2;PD-1-/- mice that had been treated with 416 
tamoxifen (0.25 mg) five days earlier. Five days after transplantation, the NSG mice were 417 
given idelalisib (S2226, Selleckchem) or vehicle (0.5% carboxymethylcellulose, 0.05% 418 
Tween 80 in ultra-pure water, C5678 and P4780, Sigma-Aldrich) by oral gavage (10 mg per 419 
kg per day) for 5 days a week. 420 
 421 
Phosflow. ITK-SYKCD4-CreERT2 mice were intraperitoneally injected with single doses of 2 mg 422 
tamoxifen (TAM) per mouse. Forty-eight hours post-injection, single-cell suspensions were 423 
generated from the spleens and lymph nodes; then, CD4+ T cells were magnetically purified 424 
(130104454, Miltenyi Biotec), and eGFP expression was assessed by flow cytometry. The 425 
cells were stimulated with recombinant PD-L1-Fc chimera protein-coated (758208, 426 
BioLegend) microspheres (CS01N, Bangs Laboratories Inc., Fishers, Indiana, USA). In brief, 427 
streptavidin-coated microspheres were first incubated with a saturating amount of biotinylated 428 
anti-human IgG antibody (409302, BioLegend) for one hour at 37 °C according to the 429 
manufacturer’s instructions. After extensive washing, these pre-coated microspheres were 430 
loaded with either PD-L1-Fc chimeric protein or control recombinant human Fc fragments 431 
(AG714, Merck Group, Darmstadt, Germany). Efficient coating was ensured by flow 432 
cytometry. After 48 hours, the cells were fixed in 4% PFA followed by methanol 433 
permeabilization, stained for p-AKT (S473, 48-9715-42, Thermo Fisher Scientific), p-PKCθ 434 
(700043, Thermo Fisher Scientific) and PTEN (9550, Cell Signaling Technology Inc., 435 
Danvers, Massachusetts, USA) and assessed by flow cytometry. The following antibodies 436 
were used as secondary antibodies: PE Donkey anti-rabbit IgG (406421, BioLegend) or PE 437 
Goat anti-mouse IgG (405307, BioLegend). 438 
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To assess PTEN, p-AKT and p-PKCθ levels in ITK-SYK+PD-1-/- lymphoma cells, TAT-CRE-439 
treated Rosa26LSL-ITK-SYK and Rosa26LSL-ITK-SYK;PD-1-/- cells were isolated from C57BL/6 440 
recipient mice (see Extended Data Fig. 6b). The single-cell suspensions were then stained for 441 
PTEN, p-AKT and p-PKCθ and analysed as above. 442 
To analyse PTEN, p-AKT and p-PKCθ levels in the PD-1- or PD-1 YFYF-transduced T-NHL 443 
cells, the GFP+ FACS-sorted cells were incubated with equal amounts of PD-L1-expressing 444 
dendritic cells for 24 hours. Afterwards, the cells were fixed and permeabilized, stained for 445 
CD3, PTEN, p-AKT and p-PKCθ and then analysed as before. 446 
To analyse the effects of idelalisib (S2226, Selleckchem) on AKT phosphorylation in vivo, 447 
5x104 lymphoma cells from TAM-treated (0.25 mg) ITK-SYKCD4-CreERT2;PD-1-/- animals were 448 
transferred into NSG recipient mice at day five after TAM injection. Five days later, the NSG 449 
mice were orally given a single dose of 10 mg/kg idelalisib or vehicle (0.5% 450 
carboxymethylcellulose, 0.05% Tween 80 in ultra-pure water). Four hours later, splenic cells 451 
were extracted from the NSG mice, fixed and permeabilized in methanol, stained for p-AKT 452 
and analysed as above. 453 
 454 
In vivo checkpoint inhibition. ITK-SYKCD4-CreERT2 mice were given single injections of 455 
tamoxifen (0.25 mg). Beginning twenty-four hours later, the mice were given 200 µg of anti-456 
PD-L1 antibody (BE0101, Bioxell, West Lebanon, New Hampshire, USA) or 200 µg anti-457 
IgG2b (BE0090, Bioxcell) control antibody diluted to 200 μl with PBS every second day. For 458 
the experiments in which the antibody treatment was started during the contraction phase, the 459 
ITK-SYKCD4-CreERT2 mice were given 200 µg of anti-PD-L1 or anti-PD-1 (BE0146, Bioxcell) 460 
antibody or anti-IgG2b (BE0090, Bioxcell) control antibody diluted to 200 μl with PBS every 461 
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third day. In all experiments, the mice were monitored by flow cytometry of the peripheral 462 
blood. 463 
 464 
Histology. All tissues were fixed in 4% formaldehyde and paraffin embedded. Approximately 465 
3–5 μm-thick sections were cut and stained with H&E. Immunohistochemistry was performed 466 
on an automated immunostainer (Agilent Technologies, Santa Clara, California, USA) using 467 
antibodies against CD3 (CI597C002, DCS, Hamburg, Germany) and Ki-67 (ab15580, 468 
Abcam, Cambridge, UK). The stained slides were evaluated by an experienced certified 469 
pathologist (K.S.) using a BX53 stereomicroscope (Olympus Corp., Shinjuku, Tokyo, Japan), 470 
classified according to the classification of lymphoid neoplasms in mice40 with respect to the 471 
most recent immunohistochemical phenotyping of rodent lymphoid tissues41 and scanned 472 
using a slide scanner (AT-2, Leica Biosystems, Wetzlar, Germany). Representative images 473 
were collected using Aperio Imagescope software (version 12.3, Leica Biosystems). 474 
 475 
Statistics. All statistical tests were performed using R3.1.3 software (R Foundation for 476 
Statistical Computing). In each experiment, the appropriate statistical tests, including non-477 
parametric tests, were used as indicated in the figure legends. Multiple comparisons were 478 
performed with ANOVA, Tukey's post-hoc test and corrected p-values. To assess the 479 
correlation between the eGFP maxima and the initial tamoxifen doses (Fig. 1a), the local 480 
maxima (reached on day 4 for the 1 mg and 0.25 mg doses and on day 8 for the 0.05 mg dose 481 
of tamoxifen) of the mean eGFP+ cell frequencies were used for Pearson coefficient 482 
calculations. The association between lymphoma development and initial eGFP+ cell 483 
frequency (Fig. 1c) was calculated based on the pooled data from two experiments. Fisher’s 484 
exact test was performed on a 2x2 contingency table that was created based on two 485 
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categorical variables: “lymphoma development” and “eGFP maximum>5% during initial 486 
expansion phase”. The variances within the groups in Fig. 1c were significantly different as 487 
determined by F-test. The normalized enrichment score (NES), false discovery rate (FDR) 488 
and p values for the GSEA were calculated with BubbleGUM33. The p-values for the common 489 
integration sites (CISs) of the PB transposon cassettes were calculated with TAPDANCE17; 490 
the p-values of “insertions” were used for CIS ranking. The upper tail of the probability 491 
density function in Fig. 2b was calculated based on the Poisson rate parameter λ derived from 492 
TAPDANCE and the Poisson cumulative distribution function (ppois) in R. No statistical 493 
methods were used to predetermine sample size estimates. P<0.05 was considered statistically 494 
significant; for the log-rank test using more than two groups, the α-level was adjusted with 495 
Bonferroni’s correction. 496 
497 
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Figure 1 | Counter-regulation of oncogenic T cell signalling in vivo.  641 
a, Frequencies of ITK-SYK-expressing eGFP+ lymphocytes in the blood of the ITK-642 
SYKCD4-CreERT2 mice following single injections of tamoxifen (n=3 mice per dose). 643 
r=Pearson’s correlation coefficient  644 
b, Gene set enrichment analyses of wild-type naïve CD4+ T cells (CD4 naïve) and 645 
ITK-SYKCD4-CreERT2 T cells at 4 (ITK-SYK 4d) and 7 days (ITK-SYK 7d) after tamoxifen 646 
injection. FDR=colour intensity of the circle. NES=circle diameter. Blue/red indicates 647 
the group in which a signature was positively enriched; n=3 biological replicates for 648 
each group. NES, normalised enrichment score; FDR, false discovery rate 649 
c, Cohorts shown in a were followed over one year (n=3 biological replicates per 650 
dose). The data in the dashed box correspond to the data in a. † indicates animals 651 
that had to be euthanized because of lymphoma. P=Fisher’s exact test. The test was 652 
performed on pooled data from two independent experiments. Representative data 653 
from one experiment are shown.  654 
655 
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Figure 2 | Identification of PDCD1 alterations in T cell lymphoma.  656 
a, Schematic representation of the transposon screen to discover T cell lymphoma 657 
genes. Transposons from the ATP2 transgene were mobilized by piggyBac in ITK-658 
SYK-expressing T cells. The tumour cells were then FACS-sorted based on eGFP 659 
expression, and the transposon insertion sites were identified by next-generation 660 
sequencing and bioinformatics analysis.  661 
b, Transposon insertion densities within pooled lymphomas (n=30 mice) for the 662 
murine chromosome 1, total: 2732 insertions and Pdcd1 locus: 23 insertions. The p-663 
value was calculated with a one-sided Poisson distribution based test, which 664 
assumes transposon insertions occurring at a constant rate. 665 
c, Flow cytometric analysis of PD-1 expression on lymphoma cells from diseased 666 
Rosa26LSL-ITK-SYK;Rosa26LSL-PB;ATP2;CD4-Cre mice. Lymphoma sample without any 667 
transposon cassette within the Pdcd1 gene (No insertion), with a single transposon 668 
cassette located in the Pdcd1 locus (Single insertion) or with multiple transposon 669 
cassettes within Pdcd1 (Multiple insertions).   670 
d, The dashed box indicates the genomic region q37.3 on human chromosome 2 that 671 
is shown in detail in the lower part of the panel (top). Mono- or bi-allelic deletions of 672 
the PDCD1 gene detected in human T cell lymphoma patients are shown (bottom). 673 
The horizontal bars indicate the regions that were affected by the CNAs. The colour 674 
of the bar indicates the type of CNA. CNA, copy number aberration; Mbp, million 675 
base pairs 676 
c, Representative results from at least 15 mice. d, Results of an analysis that 677 
included all available WGS data within one published dataset. 678 
679 
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Figure 3 | Oncogenic T cell signalling induces a PD-1 inhibitory loop.  680 
a, PD-1 expression on the peripheral blood lymphocytes from an ITK-SYKCD4-CreERT2 681 
mouse as measured by flow cytometry 96 hours after tamoxifen injection.  682 
b, Normalized transcript read counts of reads that were mapped to the Pdcd1 locus 683 
and detected in the RNAseq dataset from naïve CD4+ T cells (Naive) or ITK-SYK-684 
expressing eGFP+CD4+ T cells from ITK-SYKCD4-CreERT2 mice 4 days after the 685 
tamoxifen injection (ITK-SYK). Shown are the mean±s.e.m and individual data points. 686 
FPKM, fragments per kilobase of exon per million fragments mapped; n.d., not 687 
detectable indicates FPKM<0.1; n=3 mice per group. 688 
c, Gene Set Variation Analysis (GSVA) of fifty primary human T-NHL RNAseq 689 
samples is shown. The analysis was performed based on the geneset 690 
GO_antigen_receptor_mediated_signaling_pathway.  691 
d, PDCD1 FPKM distributions from the samples in a are shown. The T-NHL patients 692 
(n=50) were classified according to their enrichment score. P=one-sided unequal 693 
variances Student’s t-test. The FPKM distributions are shown as box plots. The 0.25-694 
, 0.5- and 0.75-quantile is depicted by the box, minimum and maximum by the 695 
whiskers. 696 
e, PDCD1 FPKM distributions from the positive samples in d are shown. The 697 
lymphomas were classified according to their PDCD1 copy number status. All T-698 
NHLs with positive enrichment score were included (n=28). P=one-sided unequal 699 
variances Student’s t-test. The FPKM distributions are shown as box plots. The 0.25-700 
, 0.5- and 0.75-quantile is depicted by the box, minimum and maximum by the 701 
whiskers; n.d., not detectable indicates FPKM<0.1. 702 
f, Intracellular flow cytometric analyses of PTEN, p-AKT and p-PKCθ levels in 703 
primary ITK-SYK-expressing T cells stimulated with PD-L1 or Fc-fragment-coated 704 
microspheres.  705 
a, Representative results from three analysed mice. f, Representative data from 706 
three independent experiments with two biological replicates per experiment. 707 
708 
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Figure 4 | PD-1 is a haploinsufficient tumour suppressor in vivo.  709 
a, ITK-SYKCD4-CreERT2 and ITK-SYKCD4-CreERT2;PD-1-/- mice (n=3 mice per genotype) 710 
received single tamoxifen injections (0.25 mg). The percentages of ITK-SYK-711 
expressing eGFP+ blood lymphocytes were determined using flow cytometry.  712 
b, Fifty million splenic cells from diseased ITK-SYKCD4-CreERT2;PD-1-/- mice (n=3 713 
donors) were intravenously transferred to NSG mice (n=3 recipients). The 714 
percentage of eGFP+ lymphocytes in the recipient’s blood is indicated. NSG, NOD 715 
SCID Il2rg−/−  716 
c, Survival of ITK-SYKCD4-CreERT2, ITK-SYKCD4-CreERT2;PD-1+/- and ITK-SYKCD4-717 
CreERT2;PD-1-/- mice (n=6, n=12 and n=14). All mice received a single tamoxifen dose 718 
on day zero. P=two-sided log-rank test  719 
d, The percentages of ITK-SYK-expressing eGFP+ peripheral blood lymphocytes of 720 
checkpoint inhibitor-treated ITK-SYKCD4-CreERT2 mice were determined by FACS. ITK-721 
SYKCD4-CreERT2 mice received single tamoxifen injections. Beginning twenty-four hours 722 
later, the mice received 200 µg of anti-PD-L1 or control antibody (n=3 mice per 723 
condition) every second day.  724 
e, Anti-CD3 antibody-stained liver section from a diseased anti-PD-L1-treated ITK-725 
SYKCD4-CreERT2 mouse from the experiment shown in d, Scale bars represent 100 µm 726 
and 20 µm (inset).  727 
f, Survival of ITK-SYKCD4-CreERT2 mice that received checkpoint inhibitor treatment 728 
starting ten days after tamoxifen administration. ITK-SYKCD4-CreERT2 mice received 729 
single injections of tamoxifen on day zero (0.25 mg). Starting ten days after injection, 730 
mice were administered 200 µg of anti-PD-L1 or anti-PD-1 antibody or control 731 
antibody (n=4 mice per condition) every third day. P=two-sided log-rank test  732 
g, Phosflow analyses of PTEN, p-AKT and p-PKCθ levels in ITK-SYK-expressing T 733 
cells isolated from the C57BL/6 recipients presented in Extended Data Figure 6b. 734 
The genotype of the transplanted cells is indicated.  735 
h, Survival of the PI3Kδ inhibitor- or vehicle-treated recipient mice. Tamoxifen-736 
induced ITK-SYKCD4-CreERT2;PD-1-/- T cells (n=5 biological replicates, 5x104 cells per 737 
transplant) were transplanted into NSG mice (n=5 recipients per group). P=two-sided 738 
log-rank test. 739 
† indicates animals that were euthanized because of lymphomas. a, Representative 740 
data from three independent experiments, each with three biological replicates. b, 741 
The data from a single experiment that was independently repeated once with 742 
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comparable results. c, Pooled data from two independent experiments. d, 743 
Representative data from four independent experiments, each with three biological 744 
replicates per antibody. e, Representative histology from one out of nine analysed 745 
mice. f, Data from a single experiment, which was repeated once with similar results. 746 
g, Representative results from two out of eight analysed mice in two independent 747 
experiments. h, Pooled survival data from two experiments. 748 
 749 
750 
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Extended Data Figure 1 | Phenotypic characterization of ITK-SYK-induced 751 
lymphomas.  752 
a, Survival curves for the ITK-SYKCD4-Cre mice and littermate controls (CD4-Cre). The 753 
p-value was determined using the two-sided log-rank test, and the median survival 754 
was 281 days vs. not reached.  755 
b, Histologies of lymph node and liver after H&E staining of tissues from a sick ITK-756 
SYKCD4-Cre mouse on a C57BL/6 genetic background. The architecture of the lymph 757 
node is disrupted by a diffuse infiltration of lymphoblastoid cells. Multinodal 758 
perivascular infiltrations of lymphoblasts are also detectable in the liver. Scale bars 759 
represent 200 µm and 20 µm (insets).  760 
c, Flow cytometric analyses of forward scatter area (FSC-A), which was used as a 761 
parameter to detect cell size, and TCRβ, CD4 and eGFP expression in lymphoma 762 
tissues from a sick ITK-SYKCD4-Cre mouse. Peripheral lymphocytes from a CD4-Cre 763 
littermate mouse served as the control.  764 
d, GeneScan analysis of TCR gene rearrangements. Fragment size distributions of 765 
fluorochrome-labelled PCR products of the Vβ1-20;Jβ2 junction demonstrating 766 
polyclonal repertoires of a healthy CD4-Cre mouse (Control), a 3-week-old ITK-767 
SYKCD4-Cre mouse and clonality of the ITK-SYKCD4-Cre lymphoma sample. RFU, 768 
relative fluorescence unit 769 
e, Survival curves for C57BL/6 mice (n=4 recipients for each donor group) which had 770 
received polyclonal ITK-SYKCD4-Cre cells (3x106) from 3-week old ITK-SYKCD4-Cre mice 771 
or clonal ITK-SYKCD4-Cre cells from diseased ITK-SYKCD4-Cre mice with lymphoma (n=4 772 
donors for each group). P=two-sided log-rank test 773 
f, Histological analysis of lymphoma samples in tamoxifen-induced ITK-SYKCD4-774 
CreERT2 animals. Lymph node with a loss of histomorphological architecture. Multifocal 775 
nodular infiltrations of lymphoblasts into kidney and lung are shown. Scale bars 776 
represent 100 µm and 20 µm (inset). 777 
g, Flow cytometric analyses of TCRβ-, CD4- and CD44-stained splenic cells in a 778 
tamoxifen-induced ITK-SYKCD4-CreERT2 mouse and wild-type littermate (Control).  779 
b, c, d, f, g, Representative data from at least ten analysed mice.  780 
781 
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Extended Data Figure 2 | Lymphomas with transposon insertions within Pdcd1. 782 
a, Overall survival of the Rosa26LSL-ITK-SYK;Rosa26LSL-PB;ATP2;CD4-Cre mice (red) 783 
and littermate ITK-SYKCD4-Cre mice (blue). The Rosa26LSL-PB;ATP2;CD4-Cre mice 784 
(black) did not display any signs of disease. The p-value was determined using two-785 
sided log-rank test, and the median survival was 255 days vs. 289 days. 786 
b, Flow cytometric analyses of TCRβ, CD4 and eGFP expression in a typical 787 
lymphoma sample from a Rosa26LSL-ITK-SYK;Rosa26LSL-PB;ATP2;CD4-Cre mouse.  788 
c, Histological analysis of the mouse shown in b with multinodal perivascular 789 
infiltrations of lymphoblasts into the liver (left) and lung (right). Scale bars represent 790 
200 µm and 20 µm (inset).  791 
d, Pdcd1 mRNA transcript levels in eGFP+ FACS-sorted peripheral lymphocytes from 792 
Rosa26LSL-ITK-SYK;Rosa26LSL-PB;ATP2;CD4-Cre lymphoma samples without any 793 
detectable transposon cassettes within the Pdcd1 locus (None, n=4) or with a single 794 
insertion (Single, n=4) or multiple Pdcd1-located transposon cassettes (Multiple, 795 
n=4). Pdcd1 expression levels were normalized to eGFP transcript levels. P=Tukey’s 796 
post hoc test. Shown are the mean±s.e.m and individual data points.  797 
e, Twenty unique transposon integration sites mapped to the murine Pdcd1 locus. 798 
The vertical black bars indicate the genomic positions of the insertion. The red 799 
arrows indicate the orientations of the transposon cassettes. 800 
f, Nucleotide sequences of the Pdcd1-piggyBac mRNA splice junctions as 801 
determined by Sanger sequencing of amplified cDNA from Rosa26LSL-ITK-802 
SYK;Rosa26LSL-PB;ATP2;CD4-Cre lymphoma samples. The cDNA was generated from 803 
sorted eGFP+ lymphoma cells in which at least one Pdcd1 transposon cassette could 804 
be detected. Note that the 5’ piggyBac transposon-specific inverted terminal repeat 805 
nucleotide sequence (PB5) can function as a cryptic splice acceptor and a splice 806 
donor site. Hence, PB5 may act as a gene trapping sequence by itself14. En2SA, 807 
exon 2 located murine Engrailed 2 splice acceptor; pA, SV40 polyadenylation signal; 808 
MSCV, murine stem cell virus long terminal repeat; LunSD, splice donor from exon 1 809 
of murine Foxf2. 810 
b, c, Representative data from at least ten analysed mice. f, The splice junctions 811 
were amplified from the cDNA of at least eight lymphomas.  812 
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Extended Data Figure 3 | PDCD1 alterations in human lymphomas. 814 
a, The dashed box indicates the genomic region q37.3 on human chromosome 2 that 815 
is shown in more detail in the middle of the panel (top). The grey horizontal bar 816 
indicates the genomic region that was affected by a PDCD1 copy number gain in T-817 
NHL patient ATL0742 (middle). Histograms showing the number of human genome-818 
aligned RNAseq reads from peripheral blood mononuclear cells (PBMCs) of two 819 
healthy donors and lymphoma cells of patient ATL074 at the PDCD1 locus and a 820 
non-coding region near the PDCD1 3’ UTR (bottom).  821 
b, The dashed box indicates the genomic region on human chromosome 2 that is 822 
shown in detail in the lower part of the panel (top). CNAs in PDCD1 that were 823 
detected in CTCL patients6 are shown (bottom). The vertical dashed lines indicate 824 
the genomic position of the PDCD1 locus. Black dots represent the logarithmic 825 
tumour/normal copy number ratio; each dot represents 1 kbp. The grey lines indicate 826 
logarithmic value of the median tumour/normal copy number ratio. The arrow 827 
indicates a bi-allelic PDCD1 loss in sample CTCL08.  828 
CNA, copy number aberration; kbp, kilo base pairs; Mbp, million base pairs 829 
830 
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Extended Data Figure 4 | Oncogenic T cell signalling induces a PD-1 inhibitory 831 
loop.  832 
a, b, Jurkat T cells (a) or primary human CD4+ T cells (b) were infected with 833 
retroviruses carrying ITK-SYK or kinase-defective ITK-SYKKD together with GFP or 834 
GFP alone (control; GFP). PD-1 surface expression was determined by flow 835 
cytometry.  836 
c, PD-1 expression after acute ITK-SYK signalling in primary T cells from tamoxifen-837 
treated ITK-SYKCD4-CreERT2 mice was assessed by a flow cytometric analysis. ITK-838 
SYKCD4-CreERT2 mice received 1 mg tamoxifen, and the cells were harvested 48 hours 839 
later, cultured in vitro and analysed at the indicated time points.  840 
a, b The data from three experiments with similar results. c Representative results 841 
from three analysed mice. 842 
 843 
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Extended Data Figure 5 | Phenotypic characterization of PD-1 deficient 845 
lymphomas. 846 
a, b, Flow cytometric analyses of TCRβ, CD4, PD-1 and eGFP expression in single-847 
cell suspensions from the spleen (a) or kidney, liver and lung (b) from an ITK-848 
SYKCD4-CreERT2;PD-1-/- mouse at one week after tamoxifen (TAM) injection. Flow 849 
cytometric analysis of forward scatter area (FSC-A) was used as a parameter to 850 
detect cell size.  851 
c, Lymph node and lung histology by H&E staining of tissues from a diseased ITK-852 
SYKCD4-CreERT2;PD-1-/- mouse one week after tamoxifen induction. The lymph node 853 
architecture was disrupted by a diffuse neoplastic lymphoid infiltration. In the lung, 854 
neoplastic lymphoid cells were located in intra- and perivascular regions with a 855 
multifocal nodal infiltration pattern. Scale bars represent 100 µm and 20 µm (inset). 856 
Scale bars represent 100 µm and 20 µm (insets).  857 
d, Histology by H&E staining of lymph node and liver tissues of an NSG recipient 858 
mouse 13 days after the transplantation of 5x107 lymphomatous ITK-SYKCD4-859 
CreERT2;PD-1-/- splenocytes. Abnormal infiltration of lymphoblastoid cells is visible. 860 
Scale bars represent 100 µm and 20 µm (insets).  861 
e, f, g Flow cytometric analysis of FSC-A and TCRβ, CD4 and eGPF expression in 862 
lymphoma cells in the spleen (e, f), kidney, liver and lung (g) from the same mouse 863 
as in d.  864 
a, b, c Representative data from three independent experiments, each with three 865 
biological replicates. d, e, f, g Representative results from one of six NSG recipient 866 
mice from two independent experiments. 867 
 868 
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Extended Data Figure 6 | Serial transplantation of PD-1-deficient lymphomas.  870 
a, Representation of the experimental strategy for inducing ITK-SYK expression via 871 
TAT-CRE in PD-1-competent (Rosa26LSL-ITK-SYK) or PD-1-deficient (Rosa26LSL-ITK-872 
SYK;PD-1-/-) cells for subsequent transfer into wild-type C57BL/6 recipient mice. 873 
b, Survival curves of the C57BL/6 recipients (n=6 recipients per genotype) 874 
transplanted with 5x105 TAT-CRE-treated Rosa26LSL-ITK-SYK or Rosa26LSL-ITK-SYK;PD-1-875 
/-CD4+ T cells (n=6 donor mice per genotype). P=two-sided log-rank test 876 
c, Flow cytometric analysis of ITK-SYK/eGFP expression in peripheral blood 877 
lymphocytes from C57BL/6 mice that received TAT-CRE-treated PD-1-competent 878 
(Rosa26LSL-ITK-SYK) or PD-1-deficient (Rosa26LSL-ITK-SYK;PD-1-/-) cells on days 7 and 21 879 
after transplantation. The genotypes of the donor mice are indicated. 880 
d, Histology and immunohistochemistry of the indicated organs from a sick primary 881 
recipient mouse after the transfer of TAT-CRE-treated Rosa26LSL-ITK-SYK;PD-1-/- T 882 
cells showing the expansion of a malignant T-lymphocyte population. Scale bars 883 
represent 100 µm (top row) and 20 µm (bottom row).  884 
e, f, Flow cytometric analysis of CD4-stained lymphocytes derived from the spleen 885 
(e) or indicated organs (f) of the mouse shown in d. FSC-A, forward scatter area, 886 
which was used as a parameter to detect cell size of splenic Rosa26LSL-ITK-SYK;PD-1-/- 887 
T cells compared to the TAT-CRE treated C57BL/6 CD4+ T cells (Control).  888 
g, Survival of secondary C57BL/6 recipient mice (n=6) that received 1x105 TAT-CRE-889 
induced Rosa26LSL-ITK-SYK;PD-1-/- lymphoma T-cells from diseased primary C57BL/6 890 
recipients (n=6 biological replicates). 891 
h, H&E-stained histologic sections from lymph node and liver tissues from a diseased 892 
C57BL/6 mouse that had received 1x105 TAT-CRE-treated Rosa26LSL-ITK-SYK;PD-1-/- T 893 
cells as the secondary recipient from a sick C57BL/6 primary recipient. Scale bars 894 
represent 100 µm and 20 µm (insets).  895 
i, j, Flow cytometric analysis as in e, f but for the secondary recipient from h.  896 
c, Characteristic flow cytometric profiles measured in two independent experiments. 897 
d, e, f, h, i, j, Representative results from one out of six analysed mice. 898 
 899 
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Extended Data Figure 7 | Characterization of Pdcd1-heterozygous lymphomas. 901 
a, Flow cytometric analysis of forward scatter area (FSC-A), which was used as a 902 
parameter to detect cell size, and TCRβ, PD-1 and eGPF expression in splenic 903 
lymphoma cells from a diseased ITK-SYKCD4-CreERT2;PD-1+/- mouse at two weeks after 904 
tamoxifen injection (0.25 mg). CD4+ T cells from an untreated wild-type C57BL/6 905 
mouse (Control) served as control.  906 
b, c, Flow cytometric analysis of CD4, eGFP and PD-1 expression in single-cell 907 
suspensions of the indicated dissociated organs from the same mouse as in a.  908 
d, Histology after H&E staining and immunohistochemical staining with anti-CD3 or 909 
anti-Ki-67 antibody of the liver tissue from the same animal as in a, b, c. Abnormal 910 
infiltration of lymphoblastoid cells is visible. Scale bars represent 100 µm and 20 µm 911 
(insets).  912 
e, Flow cytometric analyses of PD-1 receptor expression on ITK-SYK+/eGFP+ T cells 913 
from ITK-SYKCD4-CreERT2, ITK-SYKCD4-CreERT2;PD-1+/- and ITK-SYKCD4-CreERT2;PD-1-/- 914 
mice are shown.  915 
f, Flow cytometric analysis of PD-1 expression on ITK-SYK+/eGFP+ T lymphocytes. 916 
Cells isolated from the kidney, liver and lung of diseased ITK-SYKCD4-CreERT2;PD-1+/- 917 
(labelled with PD-1+/-) or ITK-SYKCD4-CreERT2;PD-1-/- (labelled with PD-1-/-) mice from 918 
the experiment presented in Fig. 4c. Shown are the mean±s.d. and individual data 919 
points; n.d., not detectable. 920 
g, Fifty million splenic cells from diseased ITK-SYKCD4-CreERT2;PD-1+/- mice (n=3 921 
donors) were intravenously transferred to NSG mice (n=3 recipients). The fold 922 
changes of ITK-SYK-expressing eGFP+ lymphocytes in the peripheral blood of the 923 
recipients are indicated. † indicates animals that had to be euthanized because of 924 
lymphomas. 925 
h, i, Flow cytometric analysis of the FSC-A, TCRβ, PD-1, CD4 and eGFP expression 926 
in spleen cell suspension (h) or lymphoma cells isolated from the lung, kidney and 927 
liver (i) of an NSG mouse that received 5x107 splenic cells from a TAM-induced ITK-928 
SYKCD4-CreERT2;PD-1+/- mouse. CD4+ T cells from an untreated wild-type C57BL/6 929 
mouse served as control.  930 
j, Spleen and liver histology after H&E staining of organ sections of the NSG recipient 931 
mouse presented in h, i. Infiltration of a lymphoblastoid cell population in the spleen 932 
resulting in a complete loss of the normal architecture. Mixed periportal and 933 
intrasinusoidal infiltrations of neutrophilic granulocytes, lymphocytes and 934 
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lymphoblasts into the liver with multifocal periportal hepatocellular necroses. Scale 935 
bars represent 100 µm and 20 µm (insets).  936 
a, b, c, d, Representative data from three independent experiments, each with at 937 
least three biological replicates. e, Histograms representing one out of three 938 
analysed mice per genotype. f, PD-1 expression on eGFP+ T cells isolated from the 939 
lung, kidney, and liver was measured in three biological replicates per genotype. g, 940 
The data from a single experiment that was independently repeated once with similar 941 
results. h, i, Representative results from one of six analysed mice from two 942 
independent experiments. j, The results are characteristic for three mice that were 943 
analysed in two independent experiments. 944 
945 
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 946 
Extended Data Figure 8 | Anti-PD-L1 triggers lethal ITK-SYK+ 947 
lymphoproliferation. 948 
a, b, c, Analyses of the antibody-treated mice from the experiment shown in Fig. 4d. 949 
Flow cytometric data of forward scatter area (FSC-A), which was used as a 950 
parameter to detect cell size, and TCRβ, CD4, PD-1 and eGPF expression in 951 
lymphomatous cells isolated from the spleen (a), kidney, liver and lung (b).  952 
c, Histology and immunohistochemistry of liver sections from the same mouse 953 
demonstrating the expansion of blastoid T-cells. Scale bars represent 100 µm and 20 954 
µm (inset).  955 
d, Fifty million splenic cells from anti-PD-L1-treated, sick ITK-SYKCD4-CreERT2 mice 956 
(n=3 biological replicates) were intravenously transferred to NSG recipient mice 957 
(n=3). The fold change of eGFP+ lymphocytes in the peripheral blood of recipients 958 
over time is shown.  959 
e, Liver and lymph node histology after H&E staining of tissue sections from a 960 
diseased ITK-SYKCD4-CreERT2 mouse from the experiment presented in Fig. 4f. The 961 
mouse received an anti-PD-1 antibody treatment that started ten days after tamoxifen 962 
administration. 963 
a, b, c, Representative data from one out of nine analysed mice in four independent 964 
experiments. d, The data from a single experiment that was repeated once with 965 
similar results. e, Histologies are characteristic for four mice that were analysed in 966 
two independent experiments. 967 
 968 
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Extended Data Figure 9 | PD-1 regulates PI3K signalling. 970 
a, Human T-NHL HuT 78 cells were infected with retroviruses carrying wild-type PD-971 
1 (PD-1) or a signalling-incompetent variant of PD-1 (PD-1 YFYF; ITIM/ITSM motifs 972 
mutated in the PD-1 cytoplasmic tail) together with GFP or GFP alone (control; GFP). 973 
PD-1 surface expression was determined by flow cytometry.  974 
b, Intracellular flow cytometric analyses of PTEN, p-AKT and p-PKCθ levels in wild-975 
type PD-1- (PD-1) or GFP only-transduced (GFP) HuT 78 cells that had been co-976 
cultured with PD-L1-expressing human dendritic cells for 24 hours.  977 
c, Intracellular flow cytometric analyses from a similar experiment as in b but with 978 
wild-type-PD-1 (PD-1) and Y223F/Y248F-mutated-PD-1 (PD-1 YFYF) transduced 979 
HuT 78 cells.  980 
d, TAT-CRE-induced Rosa26LSL-ITK-SYK;PD-1-/- cells isolated from diseased C57BL/6 981 
recipient mice (see Extended Data Fig. 6b) were cultured in vitro in the presence of 982 
the indicated concentration of the PI3Kδ inhibitor idelalisib or DMSO. Cell viability 983 
was determined over time.  984 
e, Ex vivo phosphorylation status of the AKT kinase after the oral administration of 985 
idelalisib (10 mg/kg) or vehicle into mice. ITK-SYKCD4-CreERT2;PD-1-/- T cells were 986 
induced in vivo with tamoxifen (0.25 mg). On day five after induction, 5x104 eGFP+ T 987 
cells were transplanted into NSG recipient mice. Five days later, the mice received a 988 
single gavage of idelalisib (10 mg/kg) or vehicle control. Four hours later, spleen-989 
derived single-cell suspensions were analysed by flow cytometry via Phosflow.  990 
a, Results from two independent experiments with comparable outcomes. b, c 991 
Experiments were performed three times, each with similar results. d, Experiment 992 
was performed with four biological replicates; one representative replicate is shown. 993 
e, Experiment was performed twice with similar results. 994 
995 
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 996 
Extended Data Table 1 | PDCD1 alterations in human lymphomas. 997 
Meta-analysis of five published studies containing whole-genome and whole-exome 998 
sequencing data from patients with peripheral T cell lymphoma and cutaneous T cell 999 
lymphoma. PDCD1 alterations were observed in 36 out of 158 cases (23%) across 1000 
the five studies. CNA, copy number aberration; SNV, single nucleotide variant; WES, 1001 
whole-exome sequencing; WGS, whole-genome sequencing; TS, targeted 1002 
sequencing; *, all CNAs were focal deletions; †, for CNAs see Fig. 2d.  1003 
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